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aBstraCt
introduCtion. The aim of the study was to retrospectively evaluate the efficacy of intravitreal injections of beva-
cizumab in a large group of diabetic macular edema (DME) patients.
MateriaLs and Methods. One hundred patients (125 eyes) suffering from diabetes type 1 or 2 and DME were 
treated with two or three monthly 1.25-mg intravitreal injections of bevacizumab. 
resuLts. The mean (SD) best correct visual acuity (BCVA) before treatment was 63.8 (± 26.2) letters. At months 
1, 2, and 3 the mean change (SE) in BCVA from baseline was +4.4 (± 0.49), +4.9 (0.38), and +3.1 (± 0.39) letters, 
respectively. The mean macular retinal thickness dropped from 457 (± 183) microns to 308 (± 122) microns after 
three months. The improvement of retinal morphology in optical coherence tomography was evident: a decrease in 
the number of intraretinal cysts and a generalised shrinkage of retinal macular edema. There were no serious adverse 
effects of the treatment. 
ConCLusion. The majority of patients with DME showed an improvement in visual acuity, particularly after the 
first injection of bevacizumab. Bevacizumab therapy is an interesting alternative to DME treatment.
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introduCtion
Diabetic macular edema (DME) is an accu-
mulation of fluid in the outer plexiform layer and 
inner nuclear retina as a result of leakage of retinal 
microvessels. It may occur in any stage of diabetic 
retinopathy (DR), which is the most common 
microvascular complication of both types of dia-
betes. The majority of chronic patients will devel-
op retinopathy with DME. If the edema affects 
the central part of the macula, the patient loses 
visual acuity. This is the most common symptom 
of DME [1].
An estimated 422 million people were affected 
by diabetes worldwide in 2014 [2]. The prevalence 
of diabetes has been steadily increasing for the past 
three decades, from an estimated 108 million in 
1990, and is growing most rapidly in low- and mid-
dle-income countries [3]. DR is the leading cause 
of vision loss of working-age adults, and DME is 
the most frequent cause of vision loss related to 
diabetes. The severity of visual impairment in DME 
varies depending on the type and duration of diabe-
tes. The Wisconsin Epidemiologic Study of Diabetic 
Retinopathy found the 14-year incidence of DME 
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in type 1 diabetics to be 26% [4]. Similarly, the Dia-
betes Control and Complications Trial reported that 
27% of type 1 diabetic patients develop DME with-
in nine years of onset [5]. An even higher incidence 
of macular edema has been reported in patients with 
type 2 diabetes [6].
Older onset patients have a tendency to develop 
macular edema earlier in the course of their disease 
(prevalence: 3–8% with up to three years of disease 
duration) compared to younger onset patients (pre- 
valence: 0.5% with up to 10 years of disease duration). 
In the presence of macular edema, 50% of older onset 
patients have visual acuity worse than 20/40 com-
pared to 20% of younger onset patients [4].
Bevacizumab (Avastin) is a recombinant human-
ised monoclonal antibody that binds to the receptor 
binding sequence of diffusible vascular endothe-
lial growth factor (VEGF) isoforms. This reduces 
macular edema and vascularity of epiretinal mem-
branes. Classic clinical trials do not uniformly exist; 
however, convincing data has been published for the 
most commonly treated pathologies. Bevacizumab 
is considered as an efficacious for treatment by the 
ophthalmological community.
The aim of the study was to retrospectively eval-
uate the efficacy of intravitreal injections bevaci-
zumab in a large group of DME patients.
MateriaLs and Methods
One hundred patients (125 eyes) were treated. 
The inclusion criteria consisted of the presence of 
diabetes mellitus type 1 or 2, age over 35 years, 
and macular edema of 300 μm or more. Presence 
of vitreoretinal traction, argon laser therapy in the 
past five months, or vitreoretinal surgery exclud-
ed patients from therapy. The average patient age 
was 60 years (± 14 years). The group consisted of 
48 women and 52 men. Only nine persons had 
type 1 diabetes; the others suffered from type 2 dia-
betes. Zeiss Stratus optical coherence tomography 
(OCT) was performed on qualification procedure 
(at least two weeks prior to the first injection) and 
three months after the first injection. The best cor-
rected visual acuity was evaluated using the ETDRS 
charts on qualification procedure and during the 
examination in monthly intervals. 
During the study two or three intravitreal drug 
injections were performed in 30-day intervals. OCT 
was performed on qualification procedure (at least 
two weeks prior to the first injection) and one 
month after the last injection. For three days be-
fore and three days after injections, antibiotic drops 
were administered to the eye three times daily. The 
procedure was performed under local anaesthesia in 
the operating room after washing the conjunctiva 
with 1% povidone-iodine solution. The patients 
were treated with 50 μL (1.25 mg) of bevacizumab 
administered to the vitreous body at a distance of 
3.5–4 mm from the limbus.
resuLts
The average thickness of macular retina was 
evaluated in OCT. It was marked as 457 microns 
(± 183 microns) on the baseline examination. The 
mean (SD) best correct visual acuity on the initial 
examination was 63.8 (± 26.2) letters.
A month after the first injection a marked im-
provement in visual acuity in 57 eyes was observed; 
in 46 eyes visual acuity remained unchanged. Dete-
rioration of visual acuity occurred in 22 eyes. One 
month after the second injection improvement oc-
curred in 37 eyes, and in 63 visual acuity remained 
unchanged; deterioration occurred in 25 eyes. In 
patients who had not improved during the study, the 
third injection was discontinued. After the third in-
jection in 42 eyes there was no improvement in visual 
acuity, of which in fifteen there was a deterioration. 
At Months 1, 2, and 3 the mean change (SE) in 
BCVA from baseline was +4.4 (± 0.49), +4.9 (± 0.38), 
and +3.1 (± 0.39) letters, respectively.
The improvement of retinal morphology in 
OCT was spectacular: a decrease in the number 
of intraretinal cysts and a generalised shrinkage of 
retinal macular edema. The mean central macu-
lar thickness measured in OCT was 457 microns 
(± 183 microns) on the qualification examination; 
after three months it dropped to 308 microns 
(± 122 microns) (Fig. 1).
There were no serious adverse effects of the treat-
ment. However, the following were observed:
•	 in 10.3% of patients — mild eye irritation;
•	 in 8.5% — ocular pain;
•	 in 1.7% — subconjunctival haemorrhage.
The average increase of intraocular pressure after 
injection was 3 mm Hg (± 2.5 mm Hg).
disCussion
Drugs currently registered for the treatment of 
DME are ranibizumab (Lucentis) and aflibercept 
(Eylea). Bevacizumab is a complete molecule of an 
anti-VEGF monoclonal antibody, and ranibizumab 
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Figure 1. The OCT image of a 57-year-old patient suffering from diabetes type 2. Before treatment (a) diffuse retinal edema and the pres-
ence of fluid cysts can be seen. One month after the injection (B) and after three months (C) the image has been normalised. A significant 
reduction in number of fluid cysts and a generalised decrease of macular thickness can be observed. Source: the author’s own materials 
(Department of Ophthalmology, Medical University of Gdansk, Poland)
a
B
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is only an antigen binding fragment of the antibody. 
It means that bevacizumab persists longer in the vit-
reous chamber. It is emphasised that the duration of 
a single intravitreal injection effect is six weeks, but 
no treatment effects last longer than 12 weeks [7]. 
Recent studies have confirmed the greater improve-
ment in visual acuity of patients treated with in-
jections of anti-VEGF compared to laser photo-
coagulation. Although only 25% of patients took 
advantage of the therapy [8, 9].
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Comparing our outcome with the results of oth-
er studies is challenging. Most of the studies report 
the results after long-term treatment, i.e. 6, 12, 18, 
or 24 months [10–12]. Extracting data or drawing 
conclusions for a shorter period of observation is 
not always possible. The three-month outcome of 
this study was slightly worse than described in the 
Diabetic Retinopathy Clinical Research Network 
study [10]. One of the reasons might be that the 
baseline BCVA was higher in our study 63.8 (± 26.2) 
vs. 56.6 (± 10.6). Sivaprasad et al. [13] claim that 
patients with worse initial BCVA gained more let-
ters at 12 months than those with better BCVA. 
Furthermore, in our study a drop of BCVA at week 
12 was noted. The deterioration in such an ear-
ly period, and despite ongoing treatment, differs 
from the results of other studies. Joshi et al. [14] 
claim that there might be a slight deterioration in 
visual acuity at 12 weeks of treatment, but only in 
eyes that show a decrease in central macula thick-
ness ≥ 20%. In our study such deterioration was 
observed on a large groups of patients regardless of 
the initial macular thickness. We believe that our 
results could call into question the sustainability of 
long-term anti-VEGF treatment. 
There is high-quality evidence that antiangiogenic 
drugs provide benefit compared to other therapeutic 
options for DME, i.e. grid laser photocoagulation, 
or no treatment when laser is not an option [15]. 
The quality and quantity of the evidence was larg-
er for ranibizumab, but there was little power to 
investigate drug differences [16]. Several socioec-
onomic studies emphasise the almost 30-fold dif-
ference in costs between bevacizumab and other 
FDA-approved anti-VEGF treatment [17, 18]. This 
is to outline that during the study 292 intravitreal 
injections were administered, although at the time 
of the study the Polish National Health Fund did 
not reimburse the cost of any anti-VEGF agents 
in DME.
The use of anti-VEGF intravitreal treatment 
does not cause undesirable short-term side-ef-
fects. Similar results have been found in our study. 
The safety of anti-VEGF drugs is confirmed by 
studies conducted on large groups of patients suf-
fering from age-related macular disease and DME 
[10–12, 19–21].
It may be questioned whether to expose pa-
tients to an off-label treatment since not all of them 
shall embrace the improvement of visual acuity. 
A treatment that leads to definite and permanent 
improvement in visual acuity in DME patients is 
yet unknown. Its progression is usually asymmetri-
cal, and the occurrence of vision loss in one eye is 
likely to lead to a similar situation in the other eye. 
For patients whose visual acuity does not allow read-
ing, we believe that it is worth taking the chance to 
improve the quality of vision. 
ConCLusions
Intravitreal injections of 1.25 mg of bevacizu-
mab each month in patients with DME caused 
a significant reduction of retinal edema.
In our study the majority of patients showed an 
improvement in visual acuity, particularly after the 
first injection. There were no serious adverse effects.
Bevacizumab therapy is an interesting alternative 
to DME treatment
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